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subscales such as dry mouth, stick saliva, taste impairment, and tooth 
pain the differences were found, which were both statistical (p < 
0.05) and clinically (difference >10 points) significant when compared 
with prior RT.  
Conclusions: The study showed that the most treatment-related QoL 
issues, which were deteriorated during treatment, improved in the 
first year after RT, but still dry mouth, stick saliva, taste impairment, 
and tooth pain are more pronounced than prior RT. However, these 
issues did not influence on significant difference between global QoL 
prior and 1 year after RT. 
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Purpose/Objective: To ascertain the reasons for recurrences in 
Radiation Therapy (RT), ChemoRadiation Therapy (CRT) and Surgical 
Treatment (ST) of early stages glottic laryngeal cancer. 
Materials and Methods: A retrospective analysis of 136 patients with 
SCC of the larynx T1-2 from 1992 to 2007. T1 - 67 patients, T2 - 69 
patients, including T1-2N+ 4 (2.9%) patients. 91 patients with glottic 
cancer received RT, CRT, and ST. Overall 5-year survival rate and 
median survival time: 84,4% and 82 months (Kaplan Meier Survival 
curve). Recurrences were observed in 14 (15.4%) patients, of which 
only 3 (21.4%) died from progression. 
Results: In RT and CRT - 50 patients, tumor recurrence was observed 
in 6 (12%) patients. With the defeat of the anterior commissure tumor 
(ACT) recurrence was observed in 4 (16.7%) patients, without anterior 
commissure tumor (WACT) - in 2 (7.7%) patients. The risk of 
recurrence increases by 2 times in ACT. It should be noted that 5 of 
the 6 recurrences detected after chemoradiation therapy, and 1 
patient in combination with distant metastases. After RT - only 1 
recurrence. Overall 5-year survival rate and median survival: CRT - 
87.5% and 59 months, RT - 75% and 111 months (p), respectively. Only 
2 patients died from progression. In the ST group (41 patients) - 8 
(19.5%) patients with recurrences. In 17 patients with ACT- 6 (35.3%) 
relapsed. In 24 patients WACT - 2 (8.3%) relapsed. Thus the risk of 
recurrence after surgical treatment is 4.2 times higher in patients 
with ACT and in 2 times higher compared with RT. It should be noted, 
that in 9 WACT patients received laser destruction (LD) recurrence 
detected in only 1 patient (11%). Cordectomy (CE) and partial vertical 
laryngeal resections (PVLR) performed 32 patients - relapses were 
observed in 7 (21.8%), of which CE – in 2 (12.5%) of 16 patients, PVLR - 
in 5 (31.3%) of 16. Of the these 7 patients: 2 (28.6%) with well 
differentiated tumor (WDT) and 5 (71.4%) with moderate 
differentiated tumor; surgical resections with negative margins found 
only in 1 patient. Overall 5-year survival rate and median survival - 
90.3% and 91 months. Only 1 patient died from progression. 
Conclusions: The basic reason for relapse - the incorrect treatment 
strategy. 1) The most effective treatment - radically RT, regardless of 
the degree of tumor differentiation and mode of fractionation. ACT 
increases the risk of recurrence in 2 times. 2) LD in WACT patients 
(T1a) – the same good method as RT. 3) Partial laryngeal resections 
(CE, PVLR) in WDT the same good methods as RT. ACT defeat risk of 
recurrence is 2 times higher than after RT. Perhaps a more wide 
excision of the tumor will improve the results of organ-saving 
operations. Surgical resections with pathologic margins negative for 
tumor requires additional treatment. ST needs further investigation 
and correction. 4) CRT is not inferior to other treatments in respect of 
remission of the disease, but the median survival with CRT is 2 times 
lower than with RT (p = 0.001) and 1.5 times lower than in the ST (p = 
0.01) , eliminating chemotherapy treatments for cancer of the larynx 
in the early stages. 
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Purpose/Objective: Anaplastic thyroid carcinomas (ATC) are among 
the most aggressive human malignancies. Only 1-2% of thyroid 
carcinomas are anaplastic, but the disease contributes to ≈ 50% of the 
mortality of thyroid cancers and median survival is ≤ 10 months. Our 
aim is to update recommendations for RT in the context of new 
irradiation techniques. 
Materials and Methods: A search of the French and English literature 
was performed with terms: thyroid carcinoma, anaplastic, 
chemoradiation, radiation therapy, surgery. Level-based evidence 
remains limited in the absence of prospective studies and the small 
size of retrospective series of this rare tumor. 
Results: Surgery when possible should be as complete as possible but 
without mutilation given the poor prognostic of ATC. It often consists 
of debulking resection only. It should be followed by systematic 
chemoradiation in ATC. Initiation of treatment is an emergency given 
the fast tumor doubling time of these tumors. The most promising 
results of chemoradiation to date have been shown in series of 
radiation therapy (± acceleration) combined with doxorubicin ± 
taxanes or cisplatin. Adjuvant chemotherapy (doxorubicin, cisplatine 
and/or taxane-based), given the metastatic potential of ATC, 
warrants further investigations. Data on neoadjuvant chemotherapy 
are missing. Intensity modulated radiation therapy offers clear 
dosimetric advantages and has the potential to improve tumor and 
nodal (posterior neck, mediastinum) coverage, i.e. locoregional 
control while optimally sparing the spinal cord, larynx, parotids, 
trachea and esophagus. PET-CT and MRI may be used for RT planning. 
Conclusions: Chemoradiation with debulking surgery whenever 
possible is the main stay of treatment of ATC. EBRT using IMRT has the 
potential to improve local control. Taxane-doxorubicin concomitant 
chemoradiotherapy is worth further investigations. 
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Purpose/Objective: Adenoid cystic carcinoma is a rare malignant 
neoplasma that accounts for less than 5% of head and neck cancers. 
Surgery is considered the mainstay treatment to the disease, 
however, clear surgical margins are difficult to achieve. Radiotherapy 
(RT) may improve locoregional control. The purpose of this study is to 
evaluate the effectiveness of RT for patients with head and neck 
adenoid cystic carcinoma with an attempt to identify significant 
prognostic factors. 
 Materials and Methods: A retrospective review of 25 patients who 
received RT in our department between January 2003 and May 2011 
was performed. Median age was 56 (28-79); 13 patients was female, 
12 patients was male. The subsite distribution was paranasal sinuses 
40% (n=10), oral cavity 24%(n=6), submandibular 20% (n= 5), parotid 
gland 16% (n=4). T and N stage distributions were T1:0%, T2:24%, 
T3:28%, T4:48% and N0:80%, N1:8%, N2:12%. None of the patients had 
distant metastasis at the time of diagnosis. Overall TNM stage 2, 3, 4 
distributions were 24%, 24%, 52%, respectively. Two patients had base 
of skull involvement. Ten (40%) patients had grade 3 tumor. Sixteen 
patients (64%) had microscopic perineural invasion; and 10 (40%) 
patients had positive surgical margin. Twenty-two (88%) patients had 
surgery and all patients received RT (22:postoperative, 
1:preoperative, 2:radiation alone). Conventional RT applied to 13 
patients, conformal RT applied to 12 patients. Median RT dose was 64 
Gy (40-70) with 2 Gy daily dose fraction. Six patients received 
cisplatin based chemotherapy concomitant to RT.  
Results: After median follow-up time of 46 (8.37-102) months, 18 
(72%) patients were alive (n=15 without disease, n=3 with disease) and 
7 (28%) patients were exitus. Five patients had distant, 1 patient had 
local and distant, 1 patient had local failure. Most common distant 
metastasis site was lung. Median overall survival time was 80.7 (51.75-
110) months. On univariate analysis patients with tumor stage (T4 vs 
T2+3; p=0.005) and overall stage (TNM stage 4 vs 2+3; p=0.009) 
showed worse overall survival. Close or positive surgical margin 
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compared to negative margin status was found as negative prognostic 
factors on overall survival (p=0.021). On multivariate analysis, none of 
the variables were found as significant. Median progression free 
survival time was 43 (27.4-55) months. On univariate analyisis, 
patients with paranasal sinus tumor was found worse progression free 
survival compared to other site tumors (p=0.027).  
Conclusions: Although survival rates with surgery and radiotherapy 
are relatively high and lymph node metastasis are rare, it is difficult 
to manage the disease because of its propensity for distant 
metastasis. Advanced stage with positive resection margin are 
associated with poor prognosis. 
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Purpose/Objective: SABR is increasingly considered as a standard of 
care in medically inoperable patients with early stage peripheral lung 
tumour(s). Radiation pneumonitis (RP) is more of a clinical concern in 
this population due their background lung disease .Though dosimetric 
lung parameters for conventional radiotherapy are better defined , 
such data in SABR group is limited. We present an update of a 
previous study assessing correlation between clinical toxicity and 
abnormal dosimetric parameters with more patient numbers and 
longer follow up. 
Materials and Methods: 209 patients were treated at St.James’s 
Institute of Oncology, Leeds, UK with three risk adapted SABR 
fractionations 54Gy in 3, 55Gy in 5 and 60Gy in 8 fractions from 
September 2009 to April 2012.UK SABR Consortium dose constraints 
were used for these different fractionation schedules. Various 
dosimetric parameters like R100 (ratio of 100% isodose volume to 
PTV), R50, V20, mean lung dose and D2cm(maximum dose 2cm from 
PTV in any direction) were computed for all the patients and where 
there is deviation from constraints, clinical toxicity was evaluated and 
graded according to Common Toxicity Criteria v.4.0. 
Results: At the time of analysis median follow up for the group was 21 
months (IQR 6-23 months). Mean lung dose in patients with <grade 
2(G2) toxicity was 4.2 Gy and 3.6Gy in patients with ≥G2 lung toxicity. 
50 patients (23%) had ≥ G 2 early lung toxicity (41patients G2, 9 
patients had G3 toxicity). Only 2 out of 23 patients(pts) with abnormal 
V20 developed G2 pneumonitis which resolved with steroids. 7 patients 
with high R100 (33%) developed G1to G3 early lung toxicity (2 pts G2, 
1pt-G3).The one patient with grade 3 toxicity improved with steroids. 
None of the 5 patients with high R50 had RP. Out of 30 patients with 
high D2cm (surrogate for rib dose), only 3 patients developed rib 
fractures. Mean FEV1 for patients with <G2 lung toxicity was 
1.3litres/min (0.5-3.9) and 1.2 litres/min (0.59-2.2) for patients with 
≥G2 toxicity. Median Medical Research Council (MRC) breathlessness 
score was 3.75 for patients with ≥ G2 toxicity and 3.5 for patients 
with <G2 lung toxicity. 
Conclusions: In our study, various dosimetric and clinical parameters 
did not predict for clinical toxicity. Further analysis is required to see 
if there are any other predictive metrics for lung toxicity in this 
challenging population. In addition, in this analysis we have used a 
higher D2cm as a surrogate for potential higher rib dose and we will 
perform formal dosimetric analysis of the rib dose to assess if there is 
a correlation between dose and rib toxicity 
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Purpose/Objective: In India, 63,000 new lung cancer cases are 
diagnosed annually with two-thirds in stage III and IV at presentation. 
Even in metastatic disease, predominant symptoms include chest 
symptoms for which local treatment is often required. Radiotherapy 
(RT) is an excellent modality to relieve these symptoms, however, 
optimal dose and fractionation needs to be ascertained. To assess the 
impact of short regimen RT in patients with advanced lung cancer. 
Materials and Methods: Retrospective audit of consecutive patients of 
advanced lung cancer (NSCLC & SCLC), receiving palliative thoracic 
radiotherapy (TRT) during the period from January 2012 to mid 
November 2012 was conducted. Patient related factors age, gender, 
smoking habits, predominant symptom, comorbidity, performance 
score (ECOG), tumour related factors stage, histology were recorded. 
TRT was planned using megavoltage radiation with conservative 
treatment volume by giving smaller margin to gross disease. 
Treatment related factors (RT dose,dose fractionation), use of 
systemic therapy were recorded. Subjective response to RT 
(improvement in symptom index) was recorded. Overall survival was 
calculated. 
Results: Of 68 patients treated with palliative TRT during this period 
with median age 57 years (range 24-80 years), 57 patients were males, 
31 smokers, 48.5% in stage III at presentation and 51.5% in stage IV. 
The NSCL cancer (squamous cell-26, adenocarcinoma-21, NOS-8) and 
remaining were SCLC. 38 patients had ECOG PS ≥2. The predominant 
symptoms included pain (48.5%), cough with pain (14.7%), dyspnea 
(11.8%), SVCO (11.8%), cough (7.4%), pain with dyspnea (2.9%) and 
2.9% patients had brachial plexopathy. Of these, 50 patients were 
treated with short course once weekly schedule using 16Gy/2 
fractions or 17Gy/2fractions, considering the volume to be treated. 
Seven patients did not receive second fraction due to various reasons. 
Twelve patients required analgesics for pain relief. 40 patients had 
greater than 50% relief in the symptoms after once weekly 
radiotherapy with a median duration of symptom relief of 2 months. 
42 patients received systemic treatment. At last recorded follow-up, 
17 patients had died due to disease progression. Median overall 
survival was 3.5 months. 
Conclusions: Short course RT provides good intra-thoracic symptom 
relief in advanced lung cancer patients with compromised PS. 
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Purpose/Objective: VMAT uses continuous gantry rotation to deliver 
multiple beam segments and has the advantage of faster treatment 
delivery compared to standard conformal radiotherapy. This 
technique has the theoretical advantage of better sparing of organs, 
but there is concern that larger volumes of low dose irradiation may 
increase toxicity. This study assessed if 3D conformal planning 
constraints are valid for VMAT planning and to determine toxicity and 
survival outcomes. 
Materials and Methods: Data on patients with lung carcinoma (stage I-
IIIB) and oesophageal carcinoma (stage III) who were treated with 
VMAT were obtained retrospectively. Radiotherapy treatment was 
planned using Autobeam version 4.6. Stage III lung patients received 
induction or concurrent chemotherapy, and oesophagus patients 
received induction chemotherapy followed by chemoradiotherapy. 
Patients were assessed weekly for toxicity during treatment, and then 
at 3-6 monthly intervals up to 2years. Toxicity was graded according 
to the Common Toxicity Criteria (CTC)v4.0. Doses received by the 
heart, lung, oesophagus, spinal cord, and liver were evaluated. An 
oesophageal dose constraint was not applied. Statistical analyses were 
performed to assess the relationship between dose volume parameters 
and toxicity. Outcome data was analysed using Kaplan-Meier survival 
curves. 
Results: 68 patients (42lung, 26 oesophagus) were treated between 
7/4/2008 and 31/1/2012, and received doses ranging from 50-64 Gy. 
The average age was 67.8 years (range 43-81). The median duration of 
follow-up was 11.6 months. The mean lung dose was 11.2 Gy (range 
3.13-19.41). 8.8% (6/68) and 4.4% (3/68) patients experienced≥ Grade 
2 pneumonitis at 3 and 6 months respectively. There was no 
significant correlation between pneumonitis and lung dose volume 
parameters at all levels.Overall 8/42 (19%) lung patients experienced≥ 
grade 2 oesophageal toxicity. In patients who experienced Grade 2-4 
oesophageal toxicity, median “Oesophagus V35” was 41% vs. 23% in 
those who had Grade 0-1 toxicity.Mann Whitney U test showed a 
significant difference in the V35 between these 2groups of patients. 
(U=70, p=0.00375). No late cardiac or lung toxicity ≥ Grade 2 was 
observed. Late oesophageal toxicity occurred in 4.4% (3/68). Median 
progression free survival (PFS) was 12.0 months (95% CI8.1-15.9) in 
lung patients, 7.6 months (95% CI 0.0-15.2) in oesophageal patients, 
and 11.9 months (95% CI 8.8-15.0) overall .  
Conclusions: VMAT was well tolerated by our patient cohort, with 
acceptable pneumonitis and oesophageal toxicity rates. Outcomes are 
comparable with patients treated with 3D conformal radiotherapy 
with no additional late toxicity.  
 
